Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

PERGOLIDE FOR USE IN THE TREATMENT OF EYE DISEASES ASSOCIATED WITH AN ELEVATED LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND PHARMACEUTICAL COMPOSITION CONTAINING PERGOLIDE

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    September 17, 2020
  • معلومة اضافية
    • Document Number:
      20200289480
    • Appl. No:
      16/651179
    • Application Filed:
      September 25, 2018
    • نبذة مختصرة :
      The object of the invention is pergolide for use in the treatment of eye diseases associated with an elevated level of vascular endothelial growth factor (VEGF) and a pharmaceutical composition for use in the treatment of eye diseases associated with an elevated level of vascular endothelial growth factor (VEGF), characterised in that it contains pergolide and a pharmaceutically acceptable carrier.
    • Claim:
      1. Pergolide for use in the treatment of eye diseases associated with the elevated level of vascular endothelial growth factor (VEGF).
    • Claim:
      2. Pergolide for use according to claim 1, wherein the eye disease is age-related macular degeneration (AMD).
    • Claim:
      3. Pergolide for use according to claim 2, wherein age-related macular degeneration (AMD) is wet AMD.
    • Claim:
      4. Pergolide for use according to claim 1, wherein the eye disease is diabetic macular oedema and/or diabetic retinopathy.
    • Claim:
      5. Pergolide for use according to claim 1, wherein the eye disease is retinal vessels thrombosis and/or occlusion.
    • Claim:
      6. A pharmaceutical composition for use in the treatment of eye diseases associated with the elevated level of vascular endothelial growth factor (VEGF), characterised in that it contains pergolide and a pharmaceutically acceptable carrier.
    • Claim:
      7. The pharmaceutical composition for use according to claim 6, wherein the eye disease is age-related macular degeneration (AMD).
    • Claim:
      8. The pharmaceutical composition for use according to claim 7, wherein age-related macular degeneration (AMD) is wet AMD.
    • Claim:
      9. The pharmaceutical composition for use according to claim 6, wherein the eye disease is diabetic macular oedema and/or diabetic retinopathy.
    • Claim:
      10. The pharmaceutical composition for use according to claim 6, wherein the eye disease is retinal vessels thrombosis and/or occlusion.
    • Claim:
      11. A method for treating an eye disease associated with an elevated level of vascular endothelial growth factor, the method comprising administering a pharmaceutical composition comprising a therapeutically-effective amount of Pergolide to a patient having an eye disease associated with an elevated level of vascular endothelial growth factor.
    • Claim:
      12. The method according to claim 11 wherein the eye disease is age-related macular degeneration (AMD).
    • Claim:
      13. The method according to claim 12 wherein age-related macular degeneration (AMD) is wet AMD.
    • Claim:
      14. The method according to claim 11 wherein the eye disease is diabetic macular oedema and/or diabetic retinopathy.
    • Claim:
      15. The method according to claim 11 wherein the eye disease is retinal vessels thrombosis and/or occlusion.
    • Current International Class:
      61; 61
    • الرقم المعرف:
      edspap.20200289480